Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages …
Biotechnology
US, Watertown [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Kymera Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2020 | - | -1.437 | - | 42 | - | -83 | - | -42 | - | -42 | - | 45 |
| 2021 | -2.5300 | -1.865 | 34 | 83 | -43 | -78 | -43 | -76 | -108 | -78 | 18 | 28 |
| 2022 | -2.0400 | -2.898 | 72 | 50 | -97 | -127 | -97 | -125 | -102 | -128 | 36 | 40 |
| 2023 | -2.8200 | -2.643 | 46 | 69 | -151 | -146 | -151 | -143 | -164 | -147 | 43 | 46 |
| 2024 | -2.5200 | -2.821 | 78 | 53 | -146 | -167 | -143 | -53 | -354 | -53 | 55 | 58 |
| 2025 | - | -3.067 | - | 68 | - | -162 | - | -68 | - | -68 | - | 73 |
| 2026 | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F6X/td> | - | 2.F61/td> | - | 2.F61 | - | 2.F61 |
| 2027 | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F7X/td> | - | 1.F71/td> | - | 1.F71 | - | 1.F71 |
| 2028 | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F8X/td> | - | 0.F81/td> | - | 0.F81 | - | 0.F81 |